Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- The viral phrase "the science behind Ozempic was wrong" is mostly a misreading of normal scientific refinement
- The clinical effect of semaglutide and tirzepatide is unchanged by the mechanism revisions: STEP 1 showed ~14.9% weight loss, SURMOUNT-1 showed ~22.5%
- What changed is the relative weight given to central (brain) versus peripheral (gut) mechanisms, with central appetite suppression now seen as the larger driver
- Glucagon's role, vagal afferent signaling, and reward circuitry have all received more attention as the picture has matured
- The refinement matters for next-generation drug development (retatrutide, orforglipron, cagrilintide combinations) more than for how current medications are prescribed
Direct answer
No, the science was not wrong in the sense the viral phrase suggests. Semaglutide and tirzepatide work; the clinical trial data is published, peer-reviewed, and replicated. What has shifted is the mechanistic story. Early framing emphasized peripheral effects in the gut. Newer evidence places more weight on central appetite suppression in the brain. That is a refinement, not a reversal. The drugs still produce the weight loss the trials reported.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Where the phrase comes from
- What the original mechanistic story said
- What changed and why
- The central appetite suppression story, in plain terms
- Glucagon: the contribution that got rediscovered
- What this means for clinical practice (almost nothing)
- What it means for drug development (a lot)
- The viral discourse: why this phrase spread
- What "wrong" actually means in science
- The contrary view: legitimate skeptical positions
- Decision framework for patients who saw the viral content
- FAQ
- Sources
Where the phrase comes from
"The science behind Ozempic was wrong" started circulating on TikTok and X in late 2024 and accelerated through 2025. The phrase was generally used in one of three ways:
- To accuse the pharmaceutical industry of misleading the public about how GLP-1 medications work
- To suggest the drugs only work because of nausea and forced caloric restriction
- To imply the medications are less effective or safe than the trial data shows
The first two framings are not supported by evidence. The third confuses mechanism with efficacy.
The phrase often referenced a real shift in the scientific literature: a series of papers from roughly 2018 to 2024 that increasingly emphasized central (brain-based) mechanisms over peripheral (gut-based) ones. The social media translation of that shift, however, dramatically overstated the implication. A refinement of how a drug works is not a discovery that it does not work.
What the original mechanistic story said
GLP-1 was discovered as a gut hormone. The first decade of research focused on its gut-based functions: stimulating insulin secretion after meals, suppressing glucagon, slowing gastric emptying. This framing made sense given the discovery context.
When semaglutide and earlier GLP-1 agonists (exenatide, liraglutide) were approved for type 2 diabetes, the prescribing labels emphasized:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Glucagon suppression from pancreatic alpha cells
- Delayed gastric emptying, slowing nutrient absorption
- Reduced postprandial glucose excursions
Weight loss was described as a secondary effect, attributed largely to gastric slowing producing earlier satiety and reduced caloric intake. The 2017 FDA label for Ozempic, the 2014 label for liraglutide, and most clinical reviews of the era used this framing.
The framing was not wrong in the sense of being false. The peripheral mechanisms are real. They were just emphasized at the expense of mechanisms that are now considered larger contributors.
What changed and why
Three lines of evidence pushed the mechanistic story toward the central nervous system.
Line 1: Receptor mapping. Improved immunohistochemistry and transgenic mouse models in the 2010s and early 2020s revealed that GLP-1 receptors are densely expressed in the hypothalamus (particularly the arcuate nucleus and paraventricular nucleus), the brainstem (nucleus tractus solitarius, area postrema), the hippocampus, and reward circuitry including the ventral tegmental area and nucleus accumbens. The peripheral receptors are real, but the central distribution is more extensive than initially appreciated.
Line 2: Selective receptor knockout studies. A series of papers, notably Sisley et al. (Journal of Clinical Investigation 2014) and subsequent work by Adams, Burmeister, and others, used tissue-specific receptor deletion to show that knocking out central GLP-1 receptors largely abolished the weight-loss effect of liraglutide and semaglutide in rodents. Peripheral receptor knockout did not. This was the strongest single line of evidence that the central pathway is the primary driver of weight loss.
Line 3: The food noise phenomenon. Patients on GLP-1 medications consistently described reduced food-related thoughts, not just reduced eating. The "I am not hungry" experience does not match a gastric fullness story; it matches a central appetite suppression story. Patient-reported data accumulated faster than the formal mechanistic literature and pushed researchers to take the central pathway more seriously.
By 2023, the scientific consensus had shifted. Reviews in Nature Reviews Endocrinology, Cell Metabolism, and Diabetes began describing the central appetite mechanism as the primary driver of weight loss, with peripheral effects as contributors.
The central appetite suppression story, in plain terms
The current best understanding of how GLP-1 medications cause weight loss goes roughly like this.
When semaglutide or tirzepatide reaches the brain (it crosses the blood-brain barrier via specialized regions where the barrier is permeable), it binds GLP-1 receptors in the hypothalamus and brainstem. Activation of these receptors does three things:
- Reduces signaling from neurons that promote eating (NPY/AgRP neurons)
- Increases signaling from neurons that promote satiety (POMC neurons)
- Modulates reward circuitry to reduce the appeal of palatable food
The behavioral output is reduced hunger, reduced cravings, reduced food noise, and earlier satiety even at smaller meal sizes. The patient eats less because they want less food, not because their stomach feels uncomfortably full.
The peripheral effects (gastric slowing, postprandial glucose modulation) still contribute. They likely account for some of the GI side effects, some of the glycemic effects in diabetes, and a portion of the satiety signal. But they are no longer thought to be the primary engine of weight loss.
Glucagon: the contribution that got rediscovered
One specific refinement worth flagging: the role of glucagon.
The original GLP-1 story treated glucagon suppression as a glycemic effect, helpful for diabetes by reducing hepatic glucose production. The next-generation GLP-1 / glucagon dual agonists (notably retatrutide, currently investigational and not FDA-approved) put glucagon back in the spotlight in a different way.
Glucagon, at higher doses, increases energy expenditure. The next-generation thinking, reflected in retatrutide's design, is that selectively activating glucagon receptors alongside GLP-1 can produce weight loss through both reduced intake (the GLP-1 side) and increased expenditure (the glucagon side). Early retatrutide data from the TRIUMPH trials reported weight loss exceeding 24% at the higher doses tested, suggesting the combined-mechanism approach is promising.
This is the most concrete sense in which the original mechanistic story was incomplete. Glucagon was treated as something to suppress for glycemic control. The newer view recognizes glucagon as a metabolic hormone with energy expenditure functions that, if leveraged carefully, can amplify weight loss. Retatrutide is investigational and not FDA-approved. FormBlends does not sell or supply retatrutide.
What this means for clinical practice (almost nothing)
The mechanism refinement has had almost no impact on how patients are prescribed GLP-1 medications in 2026.
- The same medications are approved for the same indications
- The same dose ladders are used
- The same monitoring approach applies
- The same patient selection criteria apply
- The same expected weight-loss outcomes apply
The reason is straightforward. Prescribing decisions are based on clinical outcomes, not mechanistic theory. The randomized controlled trials measured weight loss, glycemic control, cardiovascular outcomes, and adverse events. Those measurements do not change based on which receptor pathway is doing the most work.
What does change at the margins:
- Patient counseling can now better explain why food noise reduction is a real and expected effect, not a side effect
- The "you are just not hungry" experience is normalized rather than treated as unusual
- Comparisons across medications can reference receptor specificity (GLP-1 alone vs GLP-1/GIP vs GLP-1/GIP/glucagon)
What it means for drug development (a lot)
The mechanism refinement is reshaping the next generation of obesity pharmacotherapy.
| Drug class | Receptor activity | Status | Implications of new understanding |
|---|---|---|---|
| GLP-1 alone (semaglutide) | GLP-1 | FDA-approved | Central mechanism explains the food noise effect |
| GLP-1/GIP dual (tirzepatide) | GLP-1 + GIP | FDA-approved | GIP receptor activity may amplify central appetite effects and lean mass preservation |
| GLP-1/GIP/glucagon triple (retatrutide) | GLP-1 + GIP + glucagon | Investigational, not FDA-approved | Glucagon adds energy expenditure mechanism |
| Oral GLP-1 (orforglipron) | GLP-1 | Investigational, not FDA-approved | Small-molecule oral approach to central GLP-1 receptors |
| Amylin co-agonists (cagrilintide combinations) | GLP-1 + amylin | Investigational, not FDA-approved | Amylin adds another central satiety pathway |
| GLP-1/glucagon dual (survodutide, mazdutide) | GLP-1 + glucagon | Investigational, not FDA-approved | Tests glucagon energy expenditure hypothesis without GIP |
The whole investigational pipeline reflects the mechanism refinement. The bet is that combining receptor activities (especially central ones) and adding metabolic levers (glucagon, amylin) will produce larger weight loss with fewer side effects than single-receptor agonism. These medications are investigational and not FDA-approved. FormBlends does not sell or supply retatrutide, orforglipron, cagrilintide, cagrisema, survodutide, mazdutide, or danuglipron.
The viral discourse: why this phrase spread
The "science was wrong" framing spread for reasons that have less to do with science and more to do with how online discourse works.
Driver 1: The phrase is compact and dramatic. "The science was wrong" is six words. The actual story (mechanistic emphasis shifted from peripheral to central pathways through receptor knockout studies and clinical observation) is unshareable. The compact phrase wins.
Driver 2: Distrust of pharmaceutical companies. A non-trivial fraction of the population starts from a position of skepticism toward pharma. Any phrase that confirms that prior gets amplified, accuracy aside.
Driver 3: The economy of contrarian content. Content that pushes against the mainstream framing performs well on social platforms. "These medications work and the mechanism story is being refined" gets fewer views than "they lied to you about Ozempic."
Driver 4: Real news flowing into a misleading frame. The mechanism shift is a real story. Reporters who covered it accurately produced headlines like "How GLP-1 drugs really work has changed" that were then re-shared with the social media interpretation "GLP-1 drugs do not work the way they said."
Driver 5: Adjacent grievances. The "science was wrong" framing combines well with shortage frustrations, insurance denials, compounding controversies, and weight stigma narratives. The phrase becomes a banner that gathers unrelated grievances under one viral umbrella.
What "wrong" actually means in science
It is worth being precise about what "wrong" means when applied to scientific claims, because the casual use of the word in social media erases distinctions that matter.
Wrong as in falsified. A scientific claim is falsified when it makes a specific prediction that is tested and fails. Semaglutide weight loss is not falsified. The trials produced the predicted weight loss. The drug works.
Wrong as in fraudulent. A scientific claim is fraudulent if the underlying data was fabricated. There is no evidence of fraud in the semaglutide or tirzepatide development programs. The trial data has been audited by FDA, EMA, and independent reviewers.
Wrong as in superseded. A scientific claim can be superseded when a better explanation emerges. Newton's mechanics was not "wrong"; it was superseded by relativity in specific domains where its approximations failed. The original GLP-1 peripheral mechanism story is in this category. It was not false. It was incomplete.
Wrong as in oversimplified. A scientific claim can be wrong because it left out important contributors. The early GLP-1 story under-weighted central mechanisms. That is the most accurate critique of the original framing.
The social media phrase conflates all four meanings. The accurate version: the science was incomplete in ways that are now better understood. That is true of essentially every active area of pharmacology.
The contrary view: legitimate skeptical positions
Not every skeptical position about GLP-1 medications is a misreading. There are reasonable critiques worth airing.
Critique 1: Long-term safety data is limited. The pivotal trials are 1 to 2 years in non-diabetic populations. Multi-decade safety data, particularly for cancer risk and rare adverse events, will accumulate over time. Skeptics who emphasize this point are not wrong.
Critique 2: The trials enrolled selected populations. STEP 1 and SURMOUNT-1 excluded patients with significant psychiatric comorbidity, eating disorders, severe GI disease, and many other conditions. Real-world populations are messier than trial populations.
Critique 3: The chronic-treatment model has costs. Treating obesity as a chronic condition requiring indefinite medication is a defensible clinical position. It is also expensive, places lifetime cost on patients and insurers, and creates dependence on ongoing pharmaceutical supply. Critics who push for behavioral and structural alternatives have a point.
Critique 4: The marketing has been heavy. The promotional spending around obesity GLP-1 medications has been aggressive. The cultural conversation has been shaped in part by paid messaging. Healthy skepticism about hype is reasonable.
Critique 5: Body composition effects need more attention. The lean mass loss component of GLP-1 weight loss (25 to 40% of total loss is lean tissue per Wilding 2021 body composition data) deserves more clinical attention than it currently gets.
None of these critiques map to "the science was wrong." They map to "the science is incomplete and the clinical model has tradeoffs," which is closer to the truth.
Decision framework for patients who saw the viral content
If you encountered the "science was wrong" content and are now confused about whether to start, continue, or stop GLP-1 therapy, here is a useful structure.
If you are considering starting:
- The mechanism debate does not change the clinical evidence
- The clinical evidence (STEP 1, STEP 4, SURMOUNT-1, SURMOUNT-4, SELECT) is strong
- FDA criteria, contraindications, and side-effect profiles are unchanged
- Decide based on the clinical data, not the social media discourse
If you are currently on a GLP-1 and the viral content has shaken your confidence:
- Your medication is working through real mechanisms; the science refinement does not undermine the effect
- Continue based on your clinical response, side effects, and goals
- Bring questions to your prescriber rather than acting on social media
If you stopped because of the viral content:
- Restarting is generally an option if you were responding well
- Discuss with your prescriber before restarting
- The decision should be based on your clinical picture, not the discourse
If you are a curious bystander, not a patient:
- The phrase is misleading but reflects a real and interesting scientific story
- The underlying mechanism shift is well-summarized in Nature Reviews Endocrinology 2023 and similar review articles
- The therapeutic effect is unchanged by the mechanism refinement
FAQ
Was the science behind Ozempic wrong? Not in the sense of being false. The original mechanistic story emphasized peripheral effects; current understanding emphasizes central appetite suppression. The clinical effect is unchanged.
What is the new theory about how Ozempic works? Central appetite suppression in the brain is now considered the primary driver of weight loss, with peripheral effects contributing.
Did scientists make a mistake about Ozempic? No mistake in the sense of bad data. Hypotheses get refined as evidence accumulates.
Is Ozempic less effective than people think? The clinical effect is what the trials showed: ~14.9% weight loss in STEP 1, ~22.5% in SURMOUNT-1 for tirzepatide.
Does Ozempic only work because of nausea? No. Patients without nausea still lose weight. The central appetite mechanism operates independently of GI side effects.
What did researchers originally think about Ozempic? The original emphasis was on gastric slowing, postprandial insulin release, and reduced glucagon, framed primarily as glycemic effects.
What changed in the understanding? Receptor mapping, knockout studies, and patient-reported food noise pushed the field toward central mechanisms.
Does the new understanding change how Ozempic is prescribed? No meaningful change. Prescribing follows clinical outcomes, not mechanism theory.
Is the social media claim that Ozempic was a fraud accurate? No. There is no evidence of fraud.
Did Novo Nordisk lie about how Ozempic works? The labeling reflected the best science available at the time of approval. Subsequent refinement is not the same as misrepresentation.
What about retatrutide and the triple agonist drugs? Retatrutide is investigational and not FDA-approved. Early trial data suggests larger weight loss, consistent with the multi-receptor approach the mechanism refinement supports. FormBlends does not sell or supply retatrutide.
Should I trust the trial data? The pivotal trials are published, peer-reviewed, and have been audited by FDA and EMA. The data supports the labeled efficacy.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Rubino D et al. STEP 4 Randomized Clinical Trial. JAMA. 2021.
- Aronne LJ et al. SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Sisley S et al. Neuronal GLP-1R Mediates Liraglutide's Anorectic but Not Glucose-Lowering Effect. Journal of Clinical Investigation. 2014.
- Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metabolism. 2016.
- Muller TD et al. Glucagon-like Peptide 1 (GLP-1). Molecular Metabolism. 2019.
- Friedrichsen MH et al. The Effect of Semaglutide on Energy Intake, Appetite, and Food Preferences. Diabetes, Obesity and Metabolism. 2021.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (TRIUMPH-1). New England Journal of Medicine. 2023.
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019.
- FDA Prescribing Information. Ozempic (semaglutide) injection. Novo Nordisk. 2025 revision.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform connecting patients with independent licensed clinicians and U.S.-based pharmacies. We do not manufacture or sell medication directly. We also do not provide investigational or research-stage medications. References in this article to retatrutide, orforglipron, cagrilintide, cagrisema, survodutide, mazdutide, and danuglipron describe drugs that are investigational and not FDA-approved. FormBlends does not sell or supply any of these.
Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are prepared by 503A state-licensed compounding pharmacies in response to individual prescriptions. They are not FDA-approved and have not undergone the FDA premarket review process. They are not interchangeable with brand-name Ozempic, Wegovy, Mounjaro, or Zepbound. Mechanistic refinements in the published literature on GLP-1 receptor agonists apply to the molecules in general; clinical experience with compounded preparations may differ.
Results Disclaimer. The weight-loss percentages quoted from STEP 1, SURMOUNT-1, and other trials reflect averages observed in those specific study populations under those specific conditions. Real-world outcomes depend on adherence, dose, baseline weight, age, diet, training, and individual response.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by either company.